Pulmonx Partners with APAPP
The Association of Pulmonary Advanced Practice Providers (APAPP) and Pulmonx Corporation are excited to announce a new partnership focused on providing APP’s with breakthrough treatments for patients with COPD.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Product Feature
Zephyr® Endobronchial Valves are included in the GOLD Guidelines as part of the standard of care for the treatment of severe COPD/emphysema. They are proven to reduce breathlessness, improve exercise capacity and quality of life.1
Help your patients get back to the activities they love. Learn about patient eligibility, download resources or request information at pulmonx.com
Important Safety Information: https://pulmonx.com/prescriptive-information/
- Criner, G et al. Am J Resp Crit Care Med. 2018 Nov 1;198(9):1151-1164.
APAPP is grateful to its sponsors and donors. Through their generosity, we are able to expand our association and provide high-quality support to Nurse Practitioners and Physician Associates working in pulmonary medicine.
Interested in partnering with us? Learn more at pulmapp.com/support-us or email us at
